Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%
Executive Summary
Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.